慢性創傷 - 洞察、疫学、市場予測 2028年
Chronic Wounds Market Insights, Epidemiology, and Market Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||915406|
|出版日||ページ情報||英文 260 Pages
|慢性創傷 - 洞察、疫学、市場予測 2028年 Chronic Wounds Market Insights, Epidemiology, and Market Forecast - 2028|
|出版日: 2019年11月01日||ページ情報: 英文 260 Pages||
DelveInsight's Chronic Wounds - Market Insights, Epidemiology, and Market Forecast-2028 (G8) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Chronic Wounds in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of chronic wounds from 2017 to 2028 segmented by the eight major markets.
The current treatment market for chronic wounds is predominated by medical devices, hydrogels, and off-label antibacterial drugs. In addition to this, preventative and treatment measures of chronic wounds include disease-specific approaches, like the use of moisture-retentive dressings, bioengineered dressings, adjunctive topical therapies to promote healing, debridement, negative pressure therapy (NPWT), and Hyperbaric oxygen therapy (HBOT).
Moreover, emerging therapies, like ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), and EscharEx (MediWound), which is in the late-stage pipeline, are expected to launch during the forecast period [2019-2028]. The increasing incidence, inefficacy of present therapies, awareness of the disease, and promising emerging pipeline therapies shall propel the market size forward in the coming years.
Study Period: 2017-2028
Chronic wounds are wounds in which the normal process of healing has been disrupted at one or more points in the phases of hemostasis, inflammation, proliferation, and remodeling. In this wound type, there is usually an underlying pathology, which produces a delay in the healing process. Common skin injuries and delays or poor healing of wounds do not always turn into chronic wounds. Therefore, diagnosis depends on the patient history, which involves various risk factors, like diabetes, a weak immune system, or circulation problems. The wound can be assessed by its depth and size, color, smell, and the severity of pain and itching.
Chronic wounds are mainly caused by conditions that slow or stop the healing process, such as poor blood supply or low oxygen, an infection, weak immune system, swelling in the tissues around the wound. These are mainly classified as vascular ulcers (e.g., venous and arterial ulcers), diabetic ulcers, and pressure ulcers. Some common features shared by each of these wounds include prolonged or excessive inflammation, persistent infections, the formation of drug-resistant microbial biofilms, and the inability of dermal and/or epidermal cells to respond to reparative stimuli. In aggregate, these pathophysiologic phenomena result in the failure of these wounds to heal.
DelveInsight's chronic wounds market report gives a thorough understanding of the chronic wounds by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for chronic wounds in the US, Europe, Japan, and China.
The chronic wounds epidemiology division provides insights about historical and current patient pool and forecasted trends for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Chronic Wound in the G8 Countries, and Type-Specific Incidence of Chronic Wounds in the G8] scenario of chronic wounds in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom), Japan, and China from 2017-2028.
As per DelveInsight's analysis, the total Incident Population of Chronic Wounds in the G8 countries was found to be 26,621,142 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in China followed by the United States and among the European-5 countries, Germany had the highest incident population of chronic wounds followed by France and Italy.
On the other hand, Spain had the lowest incident population of chronic wounds. Another estimate of Delveinsight's analysis based on the type of Chronic Wounds showed that Diabetic Foot Ulcers accounted for the highest patient pool in the G8 countries, while Pressure Ulcer and Venous Ulcer cases account for nearly one-fourth, each, of the total chronic wounds population.
This segment of the chronic wounds report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The treatment and market of chronic wounds are dependent on medical devices, hydrogels, and off-label antibacterial drugs as well as emerging therapies. In emerging therapies following drugs are there ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), EscharEx (MediWound), BAY1193397 (Bayer), CSTC1 (Charsire Biotechnology), ENERGI-F703 (Energenesis Biomedical), and others.
VM202 (ViroMed BioPharma) is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms needed for optimal therapeutic benefits. Currently, VM202 is in Phase III clinical trial to assess the safety and efficacy of VM202 to treat chronic nonhealing foot ulcers in diabetic patients with the concomitant peripheral arterial disease (PAD).
On the other hand, Galnobax, by Novalead Pharma, is a topical gel of Esmolol hydrochloride for the treatment of hard to heal diabetic foot ulcers. It is a repurposed generic drug molecule, which has completed global Phase I/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both, safety and efficacy.
Another novel approach for managing these nonhealing wounds is stem-cell therapies. Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds because they have advantages as allogeneic and autologous cells. Adipose-derived stem cells (ASCs) have been demonstrated to be one of the main sources of MSCs. Anterogen is coming up with ALLO-ASC-DFU, which is allogeneic mesenchymal stem cells. This product is in late-stage of development and is expected to launch during the forecast period 2019-2028.
Additionally, Oneness Biotech also coming up with its new botanical drug ointment, ON101. Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation. According to the interim results of its ongoing phase III clinical trial, the clinical efficacy of ON101 is better than the current drug Regranex, and it will be the first natural source of therapeutic drugs for DFU with the greatest value in the market.
Another company, Tissue Tech, which is developing a product TTAX01 for the management of venous leg ulcers and nonhealing wounds. This therapy is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, cesarian section, full-term births after determination of donor eligibility and placenta suitability.
The chronic wounds market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to Delveinsight's the market size of chronic wounds was USD 6,776.76 million in 2017. The current therapeutic market of chronic wounds is the G8 countries is dependent on medical devices, hydrogels, off-label antibacterial drugs, and dressings and the expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of chronic wounds and awareness of the disease.
It was also attributed that the market size of analgesics and neuroleptics was found to be higher among the patients with Diabetic Foot Ulcers, contributing 47.46% of the Diabetic Foot Ulcer market share. This was followed by the contribution of anti-infective therapies, while for those suffering from venous ulcers, anti-infective therapies accommodate the highest share. In all G8 countries, the United States accounted for the highest market size for chronic wounds of the total G8 market in comparison to EU5, Japan and China.
Expected launch of ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), and EscharEx (MediWound) for the treatment of chronic wounds, during the forecast period [2019-2028] will create a positive impact on chronic wounds treatment market.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allowing the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of chronic wounds market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for chronic wounds.
To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of chronic wounds during our forecast period, including ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), and EscharEx (MediWound).